Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.4%

3 terminated/withdrawn out of 32 trials

Success Rate

89.7%

+3.2% vs industry average

Late-Stage Pipeline

31%

10 trials in Phase 3/4

Results Transparency

35%

9 of 26 completed trials have results

Key Signals

1 recruiting9 with results

Enrollment Performance

Analytics

Phase 2
16(50.0%)
Phase 3
9(28.1%)
Phase 1
4(12.5%)
N/A
2(6.3%)
Phase 4
1(3.1%)
32Total
Phase 2(16)
Phase 3(9)
Phase 1(4)
N/A(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials
NCT05214794Phase 2Completed

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Role: lead

NCT05240300Phase 1Withdrawn

A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

Role: collaborator

NCT01959295Phase 3Completed

Phase III Study of ASP2151 in Herpes Simplex Patients

Role: lead

NCT02209324Phase 3Completed

Open-label Study of ASP2151 in Herpes Simplex Patients

Role: lead

NCT03259620Phase 3Completed

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Role: lead

NCT02971891Phase 3Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Role: lead

NCT02970331Phase 2Withdrawn

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

Role: lead

NCT02576860Phase 3Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Role: lead

NCT02547441Phase 3Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Role: lead

NCT02576847Phase 3Completed

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

Role: lead

NCT03433820Not ApplicableCompleted

Wound Healing in Healthy Volunteers

Role: collaborator

NCT03779360Not ApplicableCompleted

Intradermal LPS and Antibiotics

Role: collaborator

NCT03684772Phase 2Unknown

Topical Ionic Contra-Viral Therapy in Actinic Keratosis

Role: lead

NCT03688971Phase 2Unknown

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Role: lead

NCT03883269Phase 4Recruiting

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Role: collaborator

NCT03334240Phase 2Terminated

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Role: lead

NCT01959841Phase 3Completed

Phase III Study of ASP2151 in Herpes Zoster Patients

Role: lead

NCT03091426Phase 2Completed

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Role: lead

NCT02596074Phase 2Completed

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Role: lead

NCT03071679Phase 1Completed

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Role: lead